ES2659577T3 - Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina - Google Patents
Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina Download PDFInfo
- Publication number
- ES2659577T3 ES2659577T3 ES05793645.2T ES05793645T ES2659577T3 ES 2659577 T3 ES2659577 T3 ES 2659577T3 ES 05793645 T ES05793645 T ES 05793645T ES 2659577 T3 ES2659577 T3 ES 2659577T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- added
- compound
- ipa
- naoh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un proceso para preparar un compuesto de fórmula I: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, que comprende: oxidar un sulfuro de fórmula II: **(Ver fórmula)** con un agente catalizador de la oxidación y un oxidante; para dar un compuesto de fórmula III: **(Ver fórmula)** seguido por la reducción catalítica del compuesto de fórmula III; para dar el compuesto de fórmula I:: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo.
Description
- Sulfona-alqueno
- 247,41 (teórico= 3,17 kg)
Se hizo una lechada del alcohol en tolueno y se agregó ácido sulfúrico. Se calentó la reacción a reflujo entre 1 y 2 horas con separación azeotrópica de agua. Al finalizar, la reacción se enfrió a 70 °C y se agregó agua. La reacción se enfrió a RT y se separaron las fases. Se agregó tolueno (6 L/kg) y NaOH 5 N (2 eq., 1,6 L/kg,
5 pH>9) a la fase acuosa manteniendo la temperatura a < 30 °C. Se separaron las fases y se trató la fase orgánica con ácido sulfúrico 1 N (1 eq. de H2SO4, ~8 L/kg, pH~1). Se separaron las fases y se transfirió la fase acuosa directamente a la reacción de oxidación.
EJEMPLO 3
- Materiales
- PM Cantidad Moles Densidad
- Sulfuro-alqueno
- 247,41 3,30 kg 13,34
- Na2WO4 x H2O
- 329,85 43,9 g 0,133
- H2O2 al 30%
- 34,01 3,78 kg (3,41 L) 33,35 1,110
- NaOH 5 N (1,5 ml/g Teórico)
- 5,6 L 12,0
- NaOH 1 N
- 5,6 L
- Solución salina al 20%
- 5,6 L
- Tolueno (5 ml/g Teórico)
- 19 L
- n-hetano
- 22,4 L
- Sulfona-alqueno
- 279,41 (Teórico: 3,73 kg) 13,34
- Na2SO3
- 126,04 0,84 kg 6,67
10
A una solución de sulfuro-alqueno en H2SO4 acuoso se agregó Na2WO4 x 2H2O. H2O2 (30%) se agregó en un periodo entre de 0,5 y 1 h manteniendo la temperatura por debajo de 55 °C. La mezcla resultante se dej ó asentar entre 50 y 55 °C hasta que el intermediario de sulfóxido alcance una cantidad de <0,5 A% (entre 1 y 2 h). La mezcla resultante se enfrió a 10 °C y se agr egó tolueno (5 L/kg) seguido por NaOH 5 N manteniendo la 15 temperatura interna <30 °C. Se separó la fase acuos a y se lavó la capa de tolueno con NaOH 1 N, seguido por un lavado con solución salina al 20%. La capa de tolueno típicamente da entre 85 y 90% de rendimiento. La reacción se concentró a 3 ml/g de volumen total (10 L) tiempo durante el cual cristalizó la sulfona-alqueno a partir de la solución. Se entibió la solución a entre 50 y 55 °C y se agregó heptano (3 mL/g) mantenie ndo la temperatura interna entre 50 y 55 °C. A la solución resultante se agregó más heptano (3 ml/g) a una
8
temperatura entre 50 y 55 °C en 1 hora. La lechada resultante se enfrió a 23 °C en un periodo de entre 0,5 y 1h, se dejó asentar durante 0,5 h y se filtró a temperatura ambiente. La torta del filtro se lavó con 1:3 tolueno/heptano (4 mL/g, 12 L) y luego se secó a 50 °C al vacío con una purga d e N2. El rendimiento típico fue entre 75 y 80 %, con >99 % en peso y 99 A% de pureza. Sobre las fases acuosas combinadas (capa acuosa después de NaOH 5 N, después de lavar con NaOH 1 N, después de lavar con solución salina al 20%) a 23 °C se agregó Na2SO3 sólido hasta que la prueba de peróxidos dio negativa mediante tiras reactivas Quantofix. Se registra una exoterma de ~3 °C.
EJEMPLO 4
en
- Materiales
- PM Cantidad Moles Densidad
- Sulfona-alqueno
- 279,41 3,00 kg 10,74
- Pd/C al 10%
- 600 g
- HCO2H
- 46,02 2,47 kg (2,03 L) 53,68 (5 eq.) 1,22
- IPA
- 15 L
- H2O
- 6 L
- Base libre
- 281,41 (Teórico = 3,02 kg) 10,74
- NaOH 5 N
- 7,5 L 37,58 (3,5 eq.)
- MTBE (10 ml/g)
- 30 L
- H2O (3 ml/g)
- 9,0 L
- HCl 5N en IPA
- 2,58 L 12,88 (1,2 eq.)
- IPA (9,2 mL/g)
- 27,6 L
- sal de HCl
- 317,88 (Teórico = 3,41 kg) 10,74
10
Se agregó HCO2H (5 eq.) a una lechada de sulfona-alqueno en IPA. A la solución resultante se agregó una suspensión de Pd/C al 10% en agua (5 ml/g). Se dejó asentar la suspensión a RT entre 16 y 24 h hasta que la sulfona-alqueno fue <0,10 A%. Se filtró el lote a través de una almohadilla de solka floc y se lavó la torta del filtro con 1:1 IPA/agua (2 mL/g). El ensayo típico de la combinación de filtrado y lavado tuvo entre 95 y 98 % de 15 rendimiento. Se transfirió el filtrado a un recipiente de extracción de 100 L conteniendo NaOH 5 N y MTBE preenfriado a 15 °C. Se separó la fase acuosa y se lavó la fase de MTBE con H2O (3 mL/g). La capa de MTBE se concentró a 4 ml/g de volumen total (12 L), se lavó rápidamente con IPA (2 x 5 ml/g) para eliminar el MTBE y el agua, luego se diluyó a 9 ml/g en IPA (contenido de H2O típico de entre 0,5 y 1%). Se entibió el filtrado a 65 °C y se agregó HCl 5 N en IPA. La lechada result ante se calentó a entre 75 y 80 °C hasta que todos los 20 sólidos estén disueltos. Se enfrió lentamente la solución se le agregó sal de HCl pura a entre 65 y 70 °C. Se
9
dejó asentar la lechada a entre 65 y 70 °C durante 1 hora y luego se enfrió lentamente a 23 °C en 1 h. Se filtró la lechada, se lavó con IPA (3 ml/g), y se secó sobre N2.
10
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61819604P | 2004-10-13 | 2004-10-13 | |
| US618196P | 2004-10-13 | ||
| PCT/EP2005/011020 WO2006040155A1 (en) | 2004-10-13 | 2005-10-13 | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2659577T3 true ES2659577T3 (es) | 2018-03-16 |
Family
ID=35478927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05793645.2T Expired - Lifetime ES2659577T3 (es) | 2004-10-13 | 2005-10-13 | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7923459B2 (es) |
| EP (1) | EP1802573B1 (es) |
| JP (1) | JP4891908B2 (es) |
| KR (1) | KR101319235B1 (es) |
| CN (1) | CN101056854B (es) |
| AU (1) | AU2005293754B2 (es) |
| CA (1) | CA2584831C (es) |
| DK (1) | DK1802573T3 (es) |
| ES (1) | ES2659577T3 (es) |
| HU (1) | HUE029790T2 (es) |
| MX (1) | MX2007004215A (es) |
| NZ (1) | NZ555094A (es) |
| PL (1) | PL1802573T3 (es) |
| WO (1) | WO2006040155A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| MXPA06013941A (es) | 2004-06-08 | 2007-12-10 | Neurosearch Sweden Ab | Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina. |
| MX2007004216A (es) * | 2004-10-13 | 2007-10-10 | Neurosearch Sweden Ab | Proceso para la sintesis de 4-(3-sulfonil)-piperidinas. |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| MX2009011020A (es) * | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) * | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) * | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| EP4741013A3 (en) | 2020-02-13 | 2026-08-05 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| CA3250337A1 (en) | 2022-05-03 | 2023-11-09 | Prilenia Neurotherapeutics Ltd. | METHODS AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE |
| IL315049A (en) | 2024-08-15 | 2026-03-01 | Prilenia Neurotherapeutics Ltd | Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
| BE662455A (es) | 1964-04-14 | |||
| GB1060160A (en) | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
| FR1459013A (fr) | 1964-08-05 | 1966-04-29 | Allen & Hanburys Ltd | Procédé de préparation de dérivés de la 4-phényl-pipéridine |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US4048314A (en) | 1974-12-17 | 1977-09-13 | Delmar Chemicals Limited | Morpholino containing 4-arylpiperidine derivatives |
| GB1560271A (en) | 1977-01-14 | 1980-02-06 | Joullie International Sa | Therapeutically useful m-trifluoromethylphenylpiperazine derivatives |
| US4202898A (en) | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
| FR2459797A2 (fr) | 1978-08-01 | 1981-01-16 | Synthelabo | Derives de phenyl-1 piperazine et leur application en therapeutique |
| US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
| US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
| GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| FR2501506A1 (fr) | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
| US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
| US4485109A (en) | 1982-05-07 | 1984-11-27 | E. I. Du Pont De Nemours And Company | 4-Aryl-4-piperidinecarbinols |
| ATE50987T1 (de) | 1982-05-10 | 1990-03-15 | Takeda Chemical Industries Ltd | Dihydropyridinderivate, deren herstellung und verwendung. |
| US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
| HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
| FR2639226B1 (fr) | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DK0641320T3 (da) | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| AU676993B2 (en) | 1991-06-27 | 1997-04-10 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| ES2162792T3 (es) | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| EP0867183B1 (en) * | 1996-07-22 | 2004-10-06 | Daiichi Suntory Pharma Co., Ltd. | Arylpiperidinol and arylpiperidine derivatives and drugs containing the same |
| US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
| DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| BR0011823A (pt) | 1999-06-22 | 2002-03-19 | Neurosearch As | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| EP1313477A4 (en) | 2000-07-15 | 2004-03-03 | Smithkline Beecham Corp | COMPILATIONS AND METHODS |
| JP2004523530A (ja) | 2001-01-23 | 2004-08-05 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体 |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| US7884104B2 (en) | 2004-10-01 | 2011-02-08 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| MX2007004216A (es) | 2004-10-13 | 2007-10-10 | Neurosearch Sweden Ab | Proceso para la sintesis de 4-(3-sulfonil)-piperidinas. |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
-
2005
- 2005-10-13 ES ES05793645.2T patent/ES2659577T3/es not_active Expired - Lifetime
- 2005-10-13 PL PL05793645T patent/PL1802573T3/pl unknown
- 2005-10-13 EP EP05793645.2A patent/EP1802573B1/en not_active Expired - Lifetime
- 2005-10-13 NZ NZ555094A patent/NZ555094A/en not_active IP Right Cessation
- 2005-10-13 WO PCT/EP2005/011020 patent/WO2006040155A1/en not_active Ceased
- 2005-10-13 KR KR1020077010900A patent/KR101319235B1/ko not_active Expired - Fee Related
- 2005-10-13 MX MX2007004215A patent/MX2007004215A/es active IP Right Grant
- 2005-10-13 CN CN2005800385910A patent/CN101056854B/zh not_active Expired - Fee Related
- 2005-10-13 JP JP2007536091A patent/JP4891908B2/ja not_active Expired - Fee Related
- 2005-10-13 DK DK05793645.2T patent/DK1802573T3/en active
- 2005-10-13 AU AU2005293754A patent/AU2005293754B2/en not_active Ceased
- 2005-10-13 CA CA2584831A patent/CA2584831C/en not_active Expired - Lifetime
- 2005-10-13 HU HUE05793645A patent/HUE029790T2/hu unknown
-
2007
- 2007-04-10 US US11/733,512 patent/US7923459B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070065911A (ko) | 2007-06-25 |
| KR101319235B1 (ko) | 2013-10-16 |
| CN101056854B (zh) | 2013-06-05 |
| US20070238879A1 (en) | 2007-10-11 |
| PL1802573T3 (pl) | 2017-03-31 |
| MX2007004215A (es) | 2007-12-12 |
| CN101056854A (zh) | 2007-10-17 |
| DK1802573T3 (en) | 2016-12-19 |
| JP2008515951A (ja) | 2008-05-15 |
| JP4891908B2 (ja) | 2012-03-07 |
| NZ555094A (en) | 2009-07-31 |
| EP1802573A1 (en) | 2007-07-04 |
| EP1802573B1 (en) | 2016-09-28 |
| HUE029790T2 (hu) | 2017-04-28 |
| AU2005293754A1 (en) | 2006-04-20 |
| US7923459B2 (en) | 2011-04-12 |
| HK1105195A1 (zh) | 2008-02-06 |
| CA2584831A1 (en) | 2006-04-20 |
| AU2005293754B2 (en) | 2011-07-21 |
| CA2584831C (en) | 2013-09-17 |
| WO2006040155A1 (en) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4795435B2 (ja) | エソメプラゾール及びその塩の製造方法 | |
| CN112047888B (zh) | 一种合成恩杂鲁胺的方法 | |
| JP2019194203A (ja) | フェブキソスタットの調製のための新規方法 | |
| SU629881A3 (ru) | Способ получени производных тиазоло (3,4 - ) изохинолина или их оптических изомеров или их солей | |
| ES2320172T3 (es) | Procedimiento para la produccion de 5-(4-(4-(5-ciano-3-indolil)-butil)-1-piperazinil)-benzofuran-2-carboxamida. | |
| EP1501824A1 (en) | A method for the purification of lansoprazole | |
| JP4485192B2 (ja) | トロペノールの工業的製造方法 | |
| CN115260118A (zh) | 一种dntf的制备方法 | |
| US4076728A (en) | Process for manufacturing crystal violet lactone | |
| ES2356501T3 (es) | Procedimiento para la preparación de zolmitriptan. | |
| CN110526913A (zh) | 一种抗凝药物阿哌沙班相关物质的制备方法 | |
| WO2022152078A1 (zh) | 一种西酞普兰或s-西酞普兰的纯化方法 | |
| CN102108049A (zh) | 9-芴甲酸的制备方法 | |
| CN116239461B (zh) | 一种苯甲酸类化合物的合成工艺 | |
| CN112239422B (zh) | 一种布格替尼中间体、其盐、其制备方法以及布格替尼的制备方法 | |
| JP5751177B2 (ja) | ルテニウム含有化合物及びその製造方法 | |
| CN110407718B (zh) | 以三苯胺为给体的苯甲酰亚胺类衍生物及其制备与应用 | |
| US10696633B2 (en) | Process for the preparation of fexofenadine and of intermediates used therein | |
| CN114989046A (zh) | 一种达伯西汀氧化杂质的合成方法 | |
| KR20250007301A (ko) | 고순도의 무정형 테고프라잔 제조방법 | |
| CN109553544B (zh) | 一种双氯芬酸钠的合成方法 | |
| US2868804A (en) | Betaine ascorbate | |
| CN107892666B (zh) | 一种5-苯基吡咯衍生物及其制备方法和用途 | |
| CN113861131A (zh) | 一种西替利嗪杂质c的制备方法 | |
| CN104072403A (zh) | 一种制备化合物unc1215的方法 |